Sign In
Buy NBY
$1.47
+0 (+0%)
At Close: Jun 08, 2026
NovaBay Pharmaceuticals Receives Australian Therapeutic Goods Administration Approval For Avenov
12:00am, Wednesday, 18'th Sep 2019NovaBay Pharmaceuticals Names Finance Executive Jeff Zheng to its Board of Directors
10:50am, Monday, 16'th Sep 2019
Dr. Zheng will chair the nominating and corporate governance committee, and will serve on the audit and compensation committees. “Jeff brings us extensive corporate governance and financial experie
NovaBay Pharmaceuticals: Empery Asset Management Report 8.42% Passive Stake
12:00am, Thursday, 15'th Aug 2019
The closing of the sale of the securities is expected to take place on or about August 13, 2019, subject to the satisfaction of customary closing conditions. The preferred stock, the common stock con
NovaBay Pharmaceuticals Announces Pricing of $4.2 Million Registered Direct Offering
01:22pm, Friday, 09'th Aug 2019
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova for the domestic eye care market, today announced that it has entered into a secur
NovaBay Pharmaceuticals' (NBY) CEO Justin Hall on Q2 2019 Results - Earnings Call Transcript
12:00am, Thursday, 08'th Aug 2019NovaBay Pharmaceuticals Q2 EPS $(0.14) Down From $(0.12) YoY, Sales $1.8M Beat $1.53M Estimate
12:00am, Wednesday, 07'th Aug 2019Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Tuesday., July 30, 2019
12:00am, Tuesday, 30'th Jul 2019NovaBay CEO Sends Letter to Shareholders Outlining Strategies
12:00am, Monday, 15'th Jul 2019NovaBay Trades Higher After Compliance Plan Accepted By NYSE
02:17pm, Monday, 01'st Jul 2019
NovaBay Pharmaceuticals (NYSE: NBY) shares are trading higher after the company said its plan of compliance was accepted by the New York Stock Exchange. NYSE notified NovaBay on April 12 and May 16 t
